AtriCure (ATRC) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
BTIG Trims PT on AtriCure (ATRC) to $19; Management 'Disconnect' Causes Concern
August 8, 2016 11:17 AM EDTBTIG cut its price target on Buy-rated AtriCure (NASDAQ: ATRC) from $34 down to $19 after the company reported Q2 results late last week.
Analyst Sean Lavin commented, ATRC reported a relatively in-line but messy quarter with the core business coming in soft while increased focus on nContact... More
Needham & Company Cuts Price Target on AtriCure (ATRC) to $20; Reiterates Buy
August 5, 2016 8:34 AM EDTNeedham & Company maintained a Buy rating on AtriCure Inc. (NASDAQ: ATRC), and cut the price target to $20.00 (from $23.00), following the company's 2Q earnings report. Revenue was reported at $39.7M, a slight beat to the consensus estimate of $39.8M. EPS was ($0.26), ahead of consensus of ($0.30). ATRC lowered its... More
AtriCure (ATRC) Guidance Reset Should Be Positive Clearing Event - Piper Jaffray
August 5, 2016 8:27 AM EDTPiper Jaffray analyst Brooks West cut his price target on AtriCure Inc. (NASDAQ: ATRC) to $17.00 (from $22.00) following Q2 results, but maintained an Overweight rating saying guidance reset could be a positive clearing event.
West commented, "AtriCure reported 2Q16 revenues of $39.7M (+21.5% cc) vs. consensus of... More

